Tirzepatide

POPULAR 2026 | RESEARCH LIBRARY

Tirzepatide

An evidence-based, plain-language information page on dual GIP/GLP-1 therapy, approved diabetes, weight-management and sleep-apnoea uses, risks and South African context.

Contents

What tirzepatide is

Important information and disclaimer

Approved and researched uses

Potential future uses

How it works

What evidence has found

South African regulatory context

How products compare

Risks and uncertainties

Treatment and measurement safeguards

Common questions

Join for updates

Sources

Important information and disclaimer

This page is for general education. Tirzepatide is a prescription medicine when supplied as an authorised product and must be prescribed and monitored for the correct indication. This page does not diagnose diabetes, obesity or sleep apnoea and does not provide personal dosing, switching, injection, reconstitution or weight-loss instructions.

Mounjaro and Zepbound are product names with different authorised indications. A vial or cartridge sold online as ‘tirzepatide’, ‘Mounjaro’, ‘research grade’ or with a certificate of analysis is not thereby equivalent to a registered medicine. Identity, peptide content, purity, sterility, excipients, concentration, stability and cold-chain history may be unknown.

Tirzepatide is not insulin and must not replace insulin in type 1 diabetes. Persistent severe abdominal pain, repeated vomiting, inability to keep fluids down, severe hypoglycaemia, sudden visual change, severe allergic symptoms or collapse requires urgent medical assessment.

What is tirzepatide?

Tirzepatide is a long-acting synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. A fatty-acid side chain promotes albumin binding and prolonged exposure, allowing authorised once-weekly injectable products.

Names and products that must not be confused

What is tirzepatide approved or researched for?

Authorised uses differ by product and country. Current US labelling includes glycaemic control in adults and children aged 10 years and older with type 2 diabetes for Mounjaro, and long-term weight reduction in defined adults plus treatment of moderate-to-severe obstructive sleep apnoea in adults with obesity for Zepbound. South African indications must be checked against current SAHPRA product information.

Glycaemic control in type 2 diabetes

Long-term body-weight reduction and maintenance in eligible adults

Moderate-to-severe obstructive sleep apnoea in adults with obesity

Effects on cardiometabolic risk factors and obesity-related complications

Preservation of weight loss during continued treatment

Potential cardiovascular, kidney, liver and heart-failure outcomes under continuing research

Trial evidence from regulated products cannot establish the quality, safety or efficacy of an informal vial or compounded copy.

Other potential uses—only if future research confirms them

Clinical programmes have investigated cardiovascular outcomes, obesity-related heart failure, metabolic liver disease, kidney outcomes, prediabetes progression and other complications of obesity. Benefits may result partly from weight loss and metabolic improvement rather than a unique direct action in every organ.

Future indications require completed trials, regulatory review and clear eligibility criteria. Tirzepatide should not be presented as an anti-ageing medicine, bodybuilding aid, universal replacement for positive-airway-pressure therapy, or treatment for type 1 diabetes.

How does tirzepatide work?

GIP and GLP-1 receptor signalling

Tirzepatide combines two incretin-receptor activities in one molecule. When glucose is elevated, it enhances insulin secretion and reduces inappropriate glucagon signalling. This improves glucose control in type 2 diabetes, but hypoglycaemia can still occur when insulin or sulfonylureas are used concurrently.

Appetite and body weight

Central and gastrointestinal signalling reduces hunger and energy intake and increases satiety. Average weight loss can be substantial, but response varies. Weight change includes fat and lean tissue, so nutritional adequacy, muscle preservation and functional outcomes matter.

Gastric emptying and prolonged exposure

Tirzepatide delays gastric emptying, particularly after early doses, and may affect absorption of oral medicines. Its long exposure supports weekly administration but also means adverse effects may persist. Oral contraceptive effectiveness can be reduced during initiation and dose escalation according to current US labels.

What has evidence found?

Type 2 diabetes

The SURPASS programme showed substantial reductions in HbA1c and body weight across several type 2 diabetes populations. Comparative studies often favoured tirzepatide over selected comparators for these endpoints, but treatment choice also depends on cardiovascular, kidney, eye, gastrointestinal, cost and access considerations.

Weight management

SURMOUNT trials demonstrated large average weight reductions in adults with obesity or overweight and related conditions. Continued treatment helped maintain loss, whereas withdrawal led to meaningful regain in many participants. Obesity commonly requires long-term management rather than a short course.

Obstructive sleep apnoea

Two 52-week randomised trials in adults with obesity and moderate-to-severe OSA showed improvement in the apnoea-hypopnoea index and body weight. The product label does not establish when positive-airway-pressure therapy should be stopped; sleep specialists should guide assessment and treatment.

Evidence and regulatory position in 2026

Current South African context

SAHPRA and the South African Pharmacy Council warned in 2026 about unlawful manufacture and supply of unregistered GLP-1/GIP medicines. South African registration, indication, presentation and professional information must be verified for the exact product. A foreign label, social-media advertisement, prescription or certificate of analysis does not authorise an unregistered supply chain.

Counterfeit, diverted and incorrectly compounded incretin products are a concern. Legitimate care requires a lawful source, the exact prescribed presentation, appropriate cold-chain control and clinical monitoring. Product availability should never be confused with permission to manufacture, compound, advertise, import or dispense.

How tirzepatide compares with related metabolic medicines

Known risks, contraindications and uncertainties

Current US labels carry a boxed warning about thyroid C-cell tumours seen in rats; human relevance is unknown. They contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN2, and with serious hypersensitivity to tirzepatide or product excipients.

Nausea, diarrhoea, reduced appetite, vomiting, constipation, indigestion and abdominal pain are common.

Severe gastrointestinal reactions can occur; use is not recommended in severe gastroparesis.

Pancreatitis, gallbladder disease, dehydration-related kidney injury and serious hypersensitivity require attention.

Hypoglycaemia risk increases with insulin or insulin secretagogues.

Rapid glucose improvement can temporarily worsen diabetic retinopathy in susceptible people.

Delayed gastric emptying creates peri-anaesthetic aspiration concerns and may affect oral medicines.

Oral contraceptive absorption may be reduced during initiation and after dose escalation.

Pregnancy and breastfeeding require product-specific professional advice.

Substantial weight loss can include lean tissue; muscle, nutrition and function should be considered.

Treatment and measurement safeguards

This page deliberately does not provide dose escalation, pen-click conversion, syringe-unit conversion, vial reconstitution, microdosing, switching equations or a compounded-product recipe. Mounjaro and Zepbound presentations vary by market and are not safely recreated from a dry vial, a volume or a claimed milligram amount.

Appropriate care may include confirming the diagnosis and exact product, glucose and kidney status, retinopathy, pancreatic or gallbladder history, gastrointestinal disease, other diabetes medicines, oral contraceptive use, pregnancy plans, nutritional risk and upcoming anaesthesia. Sleep apnoea requires objective testing and follow-up rather than judging improvement from weight alone.

Common questions

Are Mounjaro and Zepbound the same?

They contain tirzepatide but are separately authorised brands with different indications and instructions.

Is tirzepatide insulin?

No. It must never replace required insulin in type 1 diabetes.

Is it the same as semaglutide?

No. Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors.

Can tirzepatide and semaglutide be combined?

Current Zepbound labelling does not recommend coadministration with any GLP-1 receptor agonist.

Does weight stay off after stopping?

Many participants regained meaningful weight after withdrawal, so long-term planning matters.

Does OSA approval mean CPAP can be stopped?

No. The sleep-care team should decide whether and when PAP treatment changes.

Is it registered in South Africa?

The exact product, presentation and indication must be confirmed in current SAHPRA records; regulators have warned against unlawful unregistered GLP-1/GIP supply.

Join for research and regulatory updates

Join the future research bulletin for label changes, cardiovascular, kidney, liver and sleep-apnoea outcomes, South African regulatory updates and product-safety alerts. Subscription does not provide medical advice, prescriptions, product supply or personal dosing instructions.

Sources and further reading

US Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. Revised January 2026.

US Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Revised August 2026.

SAHPRA and South African Pharmacy Council. Crackdown on unlawful manufacturing of unregistered GLP-1/GIP medicines. 2026.

Frías JP, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes. New England Journal of Medicine. 2021.

Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction. JAMA. 2024.

Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity. New England Journal of Medicine. 2024.

Editorial method: current regulator labels and South African notices were prioritised, then large randomised clinical programmes. Product-specific indications were separated from molecule-level and unregistered-product claims. Review after major label or regulatory changes, and no later than March 2027.